Citigroup
TAK icon

Citigroup’s Takeda Pharmaceutical TAK Stock Holding History

Citigroup’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.36M Buy
396,457
+38,283
+11% +$633K ﹤0.01% 1942
2026
Q1 		$6.63M Buy
358,174
+339,104
+1,778% +$5.95M ﹤0.01% 1749
2025
Q4 		$297K Sell
19,070
-33,721
-64% -$482K ﹤0.01% 3820
2025
Q3 		$773K Buy
52,791
+28,816
+120% +$428K ﹤0.01% 3331
2025
Q2 		$371K Buy
23,975
+6,038
+34% +$89.2K ﹤0.01% 3787
2025
Q1 		$267K Sell
17,937
-8,059
-31% -$113K ﹤0.01% 4025
2024
Q4 		$344K Buy
25,996
+3,159
+14% +$43.4K ﹤0.01% 4068
2024
Q3 		$325K Sell
22,837
-4,676
-17% -$66.3K ﹤0.01% 4019
2024
Q2 		$356K Sell
27,513
-26,746
-49% -$354K ﹤0.01% 3594
2024
Q1 		$754K Buy
54,259
+6,283
+13% +$91.4K ﹤0.01% 3252
2023
Q4 		$685K Sell
47,976
-9,965
-17% -$141K ﹤0.01% 3157
2023
Q3 		$896K Buy
57,941
+3,089
+6% +$47.8K ﹤0.01% 2604
2023
Q2 		$862K Buy
54,852
+1,285
+2% +$21.1K ﹤0.01% 2957
2023
Q1 		$883K Buy
53,567
+2,436
+5% +$38.8K ﹤0.01% 2661
2022
Q4 		$798K Sell
51,131
-891
-2% -$12.4K ﹤0.01% 2829
2022
Q3 		$674K Sell
52,022
-883
-2% -$12.3K ﹤0.01% 3019
2022
Q2 		$743K Sell
52,905
-13,429
-20% -$192K ﹤0.01% 2921
2022
Q1 		$950K Sell
66,334
-7,723,759
-99% -$113M ﹤0.01% 3019
2021
Q4 		$106M Buy
7,790,093
+4,920,375
+171% +$69M 0.06% 304
2021
Q3 		$47M Buy
2,869,718
+2,120,154
+283% +$35.6M 0.03% 558
2021
Q2 		$12.6M Buy
749,564
+493,941
+193% +$8.41M 0.01% 1273
2021
Q1 		$4.67M Sell
255,623
-36,926
-13% -$664K ﹤0.01% 1822
2020
Q4 		$5.33M Sell
292,549
-964,253
-77% -$16.9M ﹤0.01% 2045
2020
Q3 		$22.4M Buy
1,256,802
+249,083
+25% +$4.54M 0.01% 842
2020
Q2 		$18.1M Sell
1,007,719
-19,658
-2% -$353K 0.01% 880
2020
Q1 		$15.6M Buy
1,027,377
+768,416
+297% +$13.9M 0.01% 874
2019
Q4 		$5.11M Buy
258,961
+74,915
+41% +$1.43M ﹤0.01% 2011
2019
Q3 		$3.17M Buy
184,046
+9,527
+5% +$165K ﹤0.01% 2367
2019
Q2 		$3.09M Sell
174,519
-70,636
-29% -$1.29M ﹤0.01% 2371
2019
Q1 		$4.99M Sell
245,155
-6,303,151
-96% -$127M ﹤0.01% 1783
2018
Q4 		$113M Buy
+6,548,306
New +$111M 0.11% 160

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citigroup's TAK Position: Q2 2026 in Review

Citigroup increased its Takeda Pharmaceutical (TAK) stake by 11% in Q2 2026, buying an estimated $633K and bringing the position to 396,457 shares worth $6.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1942.

Citigroup first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $113M in Q4 2018. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Citigroup held 396,457 shares of Takeda Pharmaceutical worth $6.36M as of Q2 2026.
  • Citigroup bought 38,283 Takeda Pharmaceutical shares in Q2 2026, an estimated $633K.
  • Takeda Pharmaceutical made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1942 holding.
  • Citigroup first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
  • Citigroup's Takeda Pharmaceutical position peaked at $113M in Q4 2018.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.